Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618205 | 0.93 | HDAC1 (0.69) | HDAC1KCNH2BRD4JAK1 | |
| SCHEMBL3621686 | 0.85 | HDAC1 (0.87) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL3614189 | 0.84 | HDAC1 (0.81) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL3609062 | 0.83 | HDAC1 (0.57) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL3606530 | 0.82 | HDAC1 (0.61) | HDAC1KCNH2 | |
| SCHEMBL3609407 | 0.78 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL18395945 | 0.78 | KDM4E (0.45) | HDAC1KCNH2 | |
| SCHEMBL3612049 | 0.78 | HDAC1 (0.69) | HDAC1KCNH2 | |
| SCHEMBL4898587 | 0.77 | HDAC1 (0.86) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL3615514 | 0.77 | HDAC1 (0.96) | HDAC1KCNH2HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | claimed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885KCNH2 4232/4885BRD4 113/4885 |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885KCNH2 2678/4885BRD4 44/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885KCNH2 4232/4885BRD4 113/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | HDAC1 3/4885KCNH2 4289/4885BRD4 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.